3D-QSAR and in-silico Studies of Natural Products and Related Derivatives as Monoamine Oxidase Inhibitors

Author(s): Priyanka Dhiman, Neelam Malik, Anurag Khatkar*.

Journal Name: Current Neuropharmacology

Volume 16 , Issue 6 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: The computational development of human monoamine oxidase (MAO) inhibitors led to advancement in drug design and the treatment of many neurodegenerative diseases and neuropsychiatric disorders. The computational development of human monoamine oxidase (MAO) inhibitors led to advancement in drug design and the treatment of many neurodegenerative diseases and neuropsychiatric disorders. Different natural heterocyclic structures are reported to display selective MAO inhibitory activity by preclinical and in-silico modeling.

Objective: Currently, the major interest is devoted to the study of natural based therapeutic agents from the different categories. Therefore, we presenting the review to critically discuss and outline the recent advances in our knowledge on the importance of natural and natural based ligand-MAO insilico methods for novel MAO inhibitors.

Discussion: Several natural and related synthetic heterocyclic compounds such as coumarins, β- carboline, piperine, naphthoquinone, morpholine, caffeine, amphetamine moreover flavonoids, chalcones, xanthones, curcumin are discussed for their MAO inhibitory profile along with molecular docking and quantitative structure-activity relationship studies.

Conclusion: It is clear that, by this computational drug design approach, more particular, reversible and potent compounds can be proposed as MAO inhibitors by exact changes on the fundamental framework.

Keywords: 3D-QSAR, in-silico docking, monoamine oxidase, CoMFA, natural monoamine oxidase inhibitors.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 6
Year: 2018
Page: [881 - 900]
Pages: 20
DOI: 10.2174/1570159X15666171128143650
Price: $58

Article Metrics

PDF: 27
HTML: 3